FDA approves BEI's HTA (Hydro ThermAblator) treatment for menorrhagia:
This article was originally published in Clinica
The US FDA has approved BEI Medical Systems' minimally-invasive Hydro ThermAblator (HTA) system for treating menorrhagia. The product ablates the endometrium by circulating a heated saline solution at low pressure throughout the uterus. The saline is delivered through a small sheath that includes a tiny telescope to allow the doctor to see inside the uterus before and during the procedure. The procedure can be performed on an out-patient basis under local anaesthesia in around half an hour, says BEI, of Teterboro, New Jersey.
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.